Maryland is currently home to 2666 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
NCT05051033
Recruiting
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany, Spain, Belgium and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/14/2025
Locations: The Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Mitral Valve Regurgitation
Register for Updates
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Johns Hopkins Bayview Medical, Baltimore, Maryland
Conditions: Arthritis, Psoriatic
Register for Updates
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
NCT04815356
Recruiting
Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. Researchers want to see if this treatment can help people with hairy cell leukemia (HCL). Objective: To test whether it is safe to give anti-CD22 CAR T cells to people with HCL. Eligibility: Adults ages 18 and older with HCL (classic or variant type) who have already had, are unable to r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Register for Updates
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767
Recruiting
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Register for Updates
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Register for Updates
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
NCT04324112
Recruiting
Background: Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective: To test if treatment with a combination of encorafenib and binimetinib in BRAF mutant HCL is more effective than treatment with vemurafenib. Eligibility: People ages 18 and older with BRAF... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hairy Cell Leukemia
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Medstar Union Memorial Hospital, Baltimore, Maryland
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT04123314
Recruiting
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/14/2025
Locations: Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)
NCT04104464
Recruiting
The purpose of this study is to develop a standardized assessment for patients treated for venous malformations (VM). Venous malformations result from the abnormal development of veins which may result in pain, swelling, bleeding, functional impairment, disfigurement, and psychological distress. The impact of VM on patient quality of life varies based on the location and size of the malformation. A patient reported outcome (PRO) is a patient's own account of patient's health condition. PRO mea... Read More
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
08/14/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Vascular Malformations, VM - Vascular Malformation
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Local Institution - 0092, Baltimore, Maryland
Conditions: Cancer
Register for Updates
Perception, Sensation, Cognition and Action in Humans
NCT03407066
Recruiting
Background: When people see and hear, the brain changes signals from the eyes and ears into perceptions and thoughts. No one fully understands how this happens. Researchers want to explore how healthy brains process sights and sounds. Objectives: To explore how people understand what they see and hear when the brain processes sights and sounds. Eligibility: Participants aged 13-65 who have at least 20/40 vision in at least one eye and do not use a hearing aid. Design: Some participants wi... Read More
Gender:
ALL
Ages:
Between 13 years and 65 years
Trial Updated:
08/14/2025
Locations: National Eye Institute (NEI), Bethesda, Maryland
Conditions: Normal Physiology
Register for Updates
Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder
NCT03307317
Recruiting
Background: People show changes in brain activity when they watch other people do actions. This may be part of early social and communication skills. Researchers want to understand the stages of normal development of motor observation and imitation in people and how it relates to social development in infants and toddlers. Objective: To study the nature of brain activity that underlies typical brain functioning in infants, toddlers, and adults. Eligibility: Infants ages 8 12 months Healthy... Read More
Gender:
ALL
Ages:
Between 9 months and 65 years
Trial Updated:
08/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Developmental Delay
Register for Updates